Form 4: Akero Therapeutics Executive Catriona Yale Executes Stock Option and Sells Shares

Catriona Yale, Chief Development Officer of Akero Therapeutics, exercised stock options and sold shares on September 3, 2024, according to a recent SEC filing.

Summary

• On September 3, 2024, Catriona Yale, the Chief Development Officer of Akero Therapeutics, exercised stock options to acquire 949 shares of common stock at a price of $0.615 per share.
• Simultaneously, Yale sold 949 shares of Akero Therapeutics common stock at a weighted-average price of $27.614, with individual sales ranging from $27.50 to $27.79.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 28, 2024.
• Following these transactions, Yale directly owns 75,931 shares of Akero Therapeutics common stock and 18,715 stock options.

Sentiment

Score: 5

Explanation: This is a neutral event. It's a routine disclosure of insider trading activity under a pre-arranged trading plan.

Industry Context

This filing is a routine disclosure of insider transactions. It's common for executives to exercise stock options and sell shares, especially under pre-arranged trading plans like Rule 10b5-1, which allows insiders to trade without being accused of acting on non-public information.

Stakeholder Impact

• The sale of shares by a company executive could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates concerns about insider information.

Key Dates